RESUMEN
The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compound 16) and inhaled (compound 34) PDE4 inhibitors. Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discussed.
Asunto(s)
Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/química , Oxazoles/química , Prolina/análogos & derivados , Quinolinas/síntesis química , Administración Oral , Animales , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/metabolismo , Evaluación Preclínica de Medicamentos , Semivida , Inhalación , Oxazoles/síntesis química , Oxazoles/farmacocinética , Inhibidores de Fosfodiesterasa 4/síntesis química , Inhibidores de Fosfodiesterasa 4/química , Inhibidores de Fosfodiesterasa 4/farmacocinética , Prolina/síntesis química , Prolina/química , Prolina/farmacocinética , Quinolinas/química , Quinolinas/farmacocinética , Ratas , Ratas Sprague-Dawley , Relación Estructura-ActividadRESUMEN
The structure-activity relationship studies of a novel series of carboxylic acid derivatives of pyridine-carboxamides as DGAT-1 inhibitors is described. The optimization of the initial lead compound 6 based on in vitro and in vivo activity led to the discovery of key compounds 10j and 17h.
Asunto(s)
Amidas/farmacología , Diacilglicerol O-Acetiltransferasa/antagonistas & inhibidores , Inhibidores Enzimáticos/farmacología , Piridinas/farmacología , Animales , Diacilglicerol O-Acetiltransferasa/metabolismo , Inhibidores Enzimáticos/química , Humanos , Ratones , Relación Estructura-ActividadRESUMEN
A detailed structure-activity relationship study of a novel series of pyridazine-based small molecule glucan synthase inhibitors is described. The optimization of the PK profile of this series led to the discovery of compound 11g, which demonstrated in vivo potency ip in a lethal fungal infection model.
Asunto(s)
Antifúngicos/química , Inhibidores Enzimáticos/química , Glucosiltransferasas/antagonistas & inhibidores , Piridazinas/química , Sulfonamidas/química , Animales , Antifúngicos/farmacocinética , Antifúngicos/uso terapéutico , Candida/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Inhibidores Enzimáticos/farmacocinética , Inhibidores Enzimáticos/uso terapéutico , Glucosiltransferasas/metabolismo , Semivida , Ratones , Pruebas de Sensibilidad Microbiana , Piridazinas/farmacocinética , Piridazinas/uso terapéutico , Ratas , Relación Estructura-Actividad , Sulfonamidas/farmacocinética , Sulfonamidas/uso terapéuticoRESUMEN
The structure-activity relationship studies of a novel sulfonylurea series of piperazine pyridazine-based small molecule glucan synthase inhibitors is described. The optimization of PK profiles within the series led to the discovery of several compounds with improved pharmacokinetic profiles which demonstrated in vitro potency against clinically relevant strains. However, the advancement of compounds from this series into a non-lethal systemic fungal infection model failed to show in vivo efficacy.
Asunto(s)
Antifúngicos/química , Inhibidores Enzimáticos/química , Glucosiltransferasas/antagonistas & inhibidores , Plomo/química , Piperazinas/química , Piridazinas/química , Compuestos de Sulfonilurea/química , Animales , Antifúngicos/farmacología , Candida/efectos de los fármacos , Línea Celular , Inhibidores Enzimáticos/farmacología , Humanos , Estructura Molecular , Piperazina , Piridazinas/farmacología , Ratas , Relación Estructura-Actividad , Compuestos de Sulfonilurea/farmacologíaRESUMEN
A novel series of pyridazinone analogs has been developed as potent ß-1,3-glucan synthase inhibitors through structure-activity relationship study of the lead 5-[4-(benzylsulfonyl)piperazin-1-yl]-4-morpholino-2-phenyl-pyridazin-3(2H)-one (1). The effect of changes to the core structure is described in detail. Optimization of the sulfonamide moiety led to the identification of important compounds with much improved systematic exposure while retaining good antifungal activity against the fungal strains Candida glabrata and Candida albicans.
Asunto(s)
Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacología , Glucosiltransferasas/antagonistas & inhibidores , Piridazinas/síntesis química , Piridazinas/farmacología , Antifúngicos/síntesis química , Antifúngicos/química , Antifúngicos/farmacología , Candida albicans/efectos de los fármacos , Candida glabrata/efectos de los fármacos , Inhibidores Enzimáticos/química , Estructura Molecular , Piridazinas/química , Relación Estructura-ActividadRESUMEN
A structure-activity relationship study of the lead 5-[4-(benzylsulfonyl)piperazin-1-yl]-4-morpholino-2-phenyl-pyridazin-3(2H)-one 1 has resulted in the identification of 2-(3,5-difluorophenyl)-4-(3-fluorocyclopentyloxy)-5-[4-(isopropylsulfonyl)piperazin-1-yl]-pyridazin-3(2H)-one 11c as a ß-1,3-glucan synthase inhibitor. Compound 11c exhibited significant efficacy in an in vivo mouse model of Candida glabrata infection.
Asunto(s)
Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Glucosiltransferasas/antagonistas & inhibidores , Piridazinas/química , Piridazinas/farmacología , Inhibidores Enzimáticos/síntesis química , Piridazinas/síntesis química , Relación Estructura-ActividadRESUMEN
A structure-activity relationship study of the lead piperazinylcarbonylpiperidine compound 3 resulted in the identification of 4-benzimidazolyl-piperidinylcarbonyl-piperidine 6h as a histamine-3 (H(3)) receptor antagonist. Additional optimization of 6h led to the identification of compounds 11i-k with K(i) Asunto(s)
Antagonistas de los Receptores Histamínicos H3/síntesis química
, Antagonistas de los Receptores Histamínicos H3/farmacología
, Piperidinas/síntesis química
, Piperidinas/farmacología
, Relación Estructura-Actividad
RESUMEN
The syntheses and structure-activity relationships of the tartrate-based TACE inhibitors are discussed. The optimization of both the prime and non-prime sites led to compounds with picomolar activity. Several analogs demonstrated good rat pharmacokinetics.
Asunto(s)
Proteínas ADAM/antagonistas & inhibidores , Inhibidores de Proteasas/química , Tartratos/química , Proteínas ADAM/metabolismo , Proteína ADAM17 , Animales , Sitios de Unión , Simulación por Computador , Inhibidores de Proteasas/síntesis química , Inhibidores de Proteasas/farmacocinética , Ratas , Relación Estructura-Actividad , Tartratos/síntesis química , Tartratos/farmacocinéticaRESUMEN
A strategy to overcome the side effect liabilities of oral PDE4 inhibitors has been to deliver the drugs by inhalation. In this report, we identify 1-[[5-(1(S)-aminoethly)-2-[8-methoxy-2-(triflurormethyl)-5-quinolinyl]-4-oxazolyl] carbonyl]-4(R)-[(cyclopropylcarbonyl)amino]-L-proline, ethyl ester xinafoate salt, (COMPOUND 1) as a potent and selective inhibitor of PDE4 with biological and pharmacokinetic properties suitable for delivery by the inhaled route. COMPOUND 1 potently inhibits human PDE4 (IC(50)=70pM) with little or no activity against other PDEs. It is highly potent against PDE4B and PDE4D which are important isoforms of PDE4 controlling inflammation and airway functions. In an allergen-challenged Brown Norway rat model of asthma, COMPOUND 1 inhibited the late phase influx of inflammatory cells and reductions in lung function following its administration by the intratracheal or nose-only routes of administration. Important differences were seen between intratracheal COMPOUND 1 and our previously published results with the oral PDE4 inhibitor roflumilast (Celly et al., 2005), as COMPOUND 1 rapidly (within 1h) reversed the decline in lung function when it was given therapeutically to rats already challenged with antigen. COMPOUND 1 was weakly active by the oral route which is a finding consistent with results showing this compound has poor oral bioavailability in animals. Positive interactions between COMPOUND 1 and albuterol, and COMPOUND 1 and mometasone furoate were seen on the improvement in lung functions in allergen-challenged rats. These results identify COMPOUND 1 as a potent and selective inhibitor of PDE4 with properties suitable for delivery by inhalation.
Asunto(s)
Antialérgicos/administración & dosificación , Antialérgicos/farmacología , Asma/tratamiento farmacológico , Inhibidores de Fosfodiesterasa 4/administración & dosificación , Inhibidores de Fosfodiesterasa 4/farmacología , Prolina/análogos & derivados , Quinolinas/farmacología , Administración por Inhalación , Aerosoles , Animales , Antialérgicos/sangre , Antialérgicos/farmacocinética , Antiinflamatorios/uso terapéutico , Asma/inmunología , Asma/fisiopatología , Disponibilidad Biológica , Líquido del Lavado Bronquioalveolar/citología , Broncodilatadores/uso terapéutico , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3/metabolismo , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/metabolismo , Sinergismo Farmacológico , Semivida , Humanos , Leucocitos/efectos de los fármacos , Leucocitos/enzimología , Leucocitos/metabolismo , Inhibidores de Fosfodiesterasa 4/sangre , Inhibidores de Fosfodiesterasa 4/farmacocinética , Polvos , Prolina/farmacología , Ratas , Ratas Endogámicas BN , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
A novel series of TNF-alpha convertase (TACE) inhibitors which are non-hydroxamate have been discovered. These compounds are bis-amides of L-tartaric acid (tartrate) and coordinate to the active site zinc in a tridentate manner. They are selective for TACE over other MMP's. We report the first X-ray crystal structure for a tartrate-based TACE inhibitor.
Asunto(s)
Proteínas ADAM/antagonistas & inhibidores , Proteínas ADAM/metabolismo , Descubrimiento de Drogas , Inhibidores de Proteasas/química , Tartratos/química , Factor de Necrosis Tumoral alfa/metabolismo , Proteína ADAM17 , Sitios de Unión , Técnicas Químicas Combinatorias , Cristalografía por Rayos X , Descubrimiento de Drogas/métodos , Humanos , Inhibidores de Proteasas/metabolismo , Inhibidores de Proteasas/farmacología , Tartratos/metabolismo , Tartratos/farmacologíaRESUMEN
A novel series of histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine template displaying low CYP2D6 and CYP3A4 inhibitory profiles has been identified. Structural features responsible for the reduction of P450 activity, a typical liability of 4-substituted imidazoles, have been established.
Asunto(s)
Inhibidores Enzimáticos del Citocromo P-450 , Inhibidores Enzimáticos/farmacología , Antagonistas de los Receptores Histamínicos/farmacología , Imidazoles/farmacología , Piperidinas/farmacología , Receptores Histamínicos H3/efectos de los fármacos , Animales , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Cobayas , Haplorrinos , Antagonistas de los Receptores Histamínicos/síntesis química , Antagonistas de los Receptores Histamínicos/química , Humanos , Imidazoles/síntesis química , Imidazoles/química , Estructura Molecular , Piperidinas/síntesis química , Piperidinas/química , Ratas , Relación Estructura-Actividad , Distribución TisularRESUMEN
Bipiperidine amide 1 has been identified as a CC chemokine receptor 3 (CCR3) antagonist. Optimization of its structure-activity relationship has resulted in the identification of cis (R,R)-4-[(3,4-dichlorophenyl)methyl]-3-hydroxymethyl-1'(6-quinolinylcarbonyl)-1,4'-bipiperidine 14n, which exhibits potent receptor affinity and inhibition of both calcium flux and eosinophil chemotaxis.
Asunto(s)
Amidas/síntesis química , Amidas/farmacología , Piperidinas/síntesis química , Piperidinas/farmacología , Receptores de Quimiocina/antagonistas & inhibidores , Animales , Humanos , Estructura Molecular , Receptores CCR3 , Relación Estructura-ActividadRESUMEN
A novel series of dual NK(1)/NK(2) receptor antagonists, based on the 2-oxo-(1,4'-bipiperidine) template, has been prepared. Compound 10R is a potent dual NK(1)/NK(2) antagonist and demonstrates excellent in vivo activity and good oral plasma levels in the dog.